Vrancken Louise, Muller Joséphine, Lejeune Margaux, Gregoire Céline, Delens Loïc, Jaspers Aurélie, Servais Sophie, Prijck Bernard, Baron Frédéric, Caers Jo, Beguin Yves
Service d'hématologie, CHU Liège, 4000 Liège, Belgique.
Laboratoire d'hématologie, GIGA-I³, Université de Liège, 4000 Belgique.
Rev Med Suisse. 2018 Aug 22;14(615):1438-1442.
Multiple myeloma is the second most frequent hematological malignancy. Unfortunately, it is still incurable. A better understanding of the myeloma pathophysiology favored the development of new therapeutic molecules that improved both survival and quality of life of patients. Diagnostic and prognostic criteria for myeloma have been reviewed and help to detect multiple myeloma more early and further help to define the best therapeutic strategy. These new regimens are associated with side effects that differ from those of classic molecules and that we have to be able to recognize and to treat appropriately.
多发性骨髓瘤是第二常见的血液系统恶性肿瘤。不幸的是，它仍然无法治愈。对骨髓瘤病理生理学的更好理解推动了新治疗分子的研发，这些分子改善了患者的生存率和生活质量。骨髓瘤的诊断和预后标准已得到重新审视，有助于更早地检测多发性骨髓瘤，并进一步帮助确定最佳治疗策略。这些新方案会带来与传统分子不同的副作用，我们必须能够识别并进行适当治疗。
